IL17A and benign prostatic hyperplasia: For creating in vitro chronic BPH inflammation model, ihPSC were grown in the presence of IFN-γ+IL-17 (20 ng/ mL for each) [17] and then the effects of IFN-γ+IL-17 on the viability of ihPSC was determined after 48 h treatment (Fig 5A).